Meeting
2023 ASCO Genitourinary Cancers Symposium
Clinical outcomes after utilization of PSMA PET scans in patients with biochemical recurrent prostate cancer.
Authors
Irene Tsung
Michigan Medicine, Ann Arbor, MI
Irene Tsung , Stephen Hynes , Urvashi Mitbander Joshi , Krystal A Morales , Robert Timothy Dess , William C. Jackson , Jeremy MG Taylor , Zachery R Reichert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 57)
DOI
10.1200/JCO.2023.41.6_suppl.57
Abstract #
57
Poster Bd #
B13
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
First Author: Luke T. Nordquist
Poster
2020 ASCO Virtual Scientific Program
Prospective evaluation of 18F-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.
First Author: Hong Song
Poster
2015 ASCO Annual Meeting
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.
First Author: Tobias Maurer
Poster
2024 ASCO Genitourinary Cancers Symposium
Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.
First Author: Ahmed M. Mahmoud